Tags

Type your tag names separated by a space and hit enter

Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients.
Am J Hypertens. 1998 Jan; 11(1 Pt 2):15S-22S.AJ

Abstract

Carvedilol is a new beta-blocker antihypertensive agent with vasodilating properties secondary to alpha 1-blocking activity. Peripheral vascular resistance is reduced and cardiac output and renal function are not altered with carvedilol. The antihypertensive effects of this agent are equivalent to those of other beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, and diuretics. Carvedilol has a neutral effect on lipids and glucose metabolism. The percentage of responders is increased when carvedilol is combined with a diuretic. This agent has several unique properties. In addition to its antihypertensive effects, carvedilol in vitro and in vivo has been shown to have antiproliferative effects on smooth muscle cells and to inhibit the action of oxygen-free radicals. The antioxidant properties of this compound are significantly greater than those of vitamin E. In animal models, carvedilol may slow the process of atherogenesis, reduce infarct size, and improve postinfarction survival to a greater degree than other beta-blockers. Recent studies have demonstrated that carvedilol reduces morbidity and mortality in patients with congestive heart failure who are already receiving angiotensin converting enzyme inhibitors, diuretics, and digitalis. The antioxidant and antiproliferative activities of carvedilol may present an advantage over other available antihypertensive medications.

Authors+Show Affiliations

Yale University School of Medicine, New Haven, Connecticut, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9503102

Citation

Moser, M, and W Frishman. "Results of Therapy With Carvedilol, a Beta-blocker Vasodilator With Antioxidant Properties, in Hypertensive Patients." American Journal of Hypertension, vol. 11, no. 1 Pt 2, 1998, 15S-22S.
Moser M, Frishman W. Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens. 1998;11(1 Pt 2):15S-22S.
Moser, M., & Frishman, W. (1998). Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. American Journal of Hypertension, 11(1 Pt 2), 15S-22S.
Moser M, Frishman W. Results of Therapy With Carvedilol, a Beta-blocker Vasodilator With Antioxidant Properties, in Hypertensive Patients. Am J Hypertens. 1998;11(1 Pt 2):15S-22S. PubMed PMID: 9503102.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. AU - Moser,M, AU - Frishman,W, PY - 1998/3/21/pubmed PY - 1998/3/21/medline PY - 1998/3/21/entrez SP - 15S EP - 22S JF - American journal of hypertension JO - Am J Hypertens VL - 11 IS - 1 Pt 2 N2 - Carvedilol is a new beta-blocker antihypertensive agent with vasodilating properties secondary to alpha 1-blocking activity. Peripheral vascular resistance is reduced and cardiac output and renal function are not altered with carvedilol. The antihypertensive effects of this agent are equivalent to those of other beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, and diuretics. Carvedilol has a neutral effect on lipids and glucose metabolism. The percentage of responders is increased when carvedilol is combined with a diuretic. This agent has several unique properties. In addition to its antihypertensive effects, carvedilol in vitro and in vivo has been shown to have antiproliferative effects on smooth muscle cells and to inhibit the action of oxygen-free radicals. The antioxidant properties of this compound are significantly greater than those of vitamin E. In animal models, carvedilol may slow the process of atherogenesis, reduce infarct size, and improve postinfarction survival to a greater degree than other beta-blockers. Recent studies have demonstrated that carvedilol reduces morbidity and mortality in patients with congestive heart failure who are already receiving angiotensin converting enzyme inhibitors, diuretics, and digitalis. The antioxidant and antiproliferative activities of carvedilol may present an advantage over other available antihypertensive medications. SN - 0895-7061 UR - https://www.unboundmedicine.com/medline/citation/9503102/Results_of_therapy_with_carvedilol_a_beta_blocker_vasodilator_with_antioxidant_properties_in_hypertensive_patients_ L2 - https://academic.oup.com/ajh/article-lookup/doi/10.1016/s0895-7061(97)00424-x DB - PRIME DP - Unbound Medicine ER -